GSK to Acquire BELLUS Health for ~$2.0B
Shots:
- GSK will acquire BELLUS Health for $14.75 per share in cash representing a total equity value of ~$2.0B at a premium of ~103% to BELLUS' closing stock price. The transaction is expected to close in Q3'23
- The acquisition gives GSK access to camlipixant (highly selective P2X3 antagonist) for adult patients with RCC. The acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant
- Camlipixant is currently in P-III clinical development with anticipated regulatory approval & launch in 2026. In the P-IIb trial (SOOTHE) trial, camlipixant was shown to be effective at reducing 24hr. cough frequency with BID, 50 & 200mg oral dosing & 34% reduction in the rate vs PBO at 28 Day
Ref: GSK | Image: GSK
Related News:- GSK Reports EMA’s Validation of MAA for Jemperli (dostarlimab) to Treat dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
